Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer

M Kohli; W Tan; T Zheng; A Wang; C Montesinos; C Wong; P Du; S Jia; S Yadav; LG Horvath; KL Mahon; EM Kwan; H Fettke; J Yu; AA Azad

Journal article

Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer

M Kohli, W Tan, T Zheng, A Wang, C Montesinos, C Wong, P Du, S Jia, S Yadav, LG Horvath, KL Mahon, EM Kwan, H Fettke, J Yu, AA Azad

Ebiomedicine | ELSEVIER | Published : 2020

DOI: 10.1016/j.ebiom.2020.102728

Open access

Download PDF

Abstract

Background: Metastatic prostate cancer is a clonally heterogeneous disease state characterized by progressive somatic perturbations. The aim of this study was to identify cell free DNA- (cfDNA-) based alterations and their associations with outcomes in progressive metastatic prostate cancer. Methods: In this longitudinal prospective cohort study plasma cfDNA/circulating tumor DNA (ctDNA) was analyzed before, during, and after androgen deprivation therapy (ADT) in 4 independent patient groups ranging from untreated metastatic hormone sensitive prostate cancer (mHSPC) to metastatic castrate resistant prostate cancer (mCRPC). Next generation sequencing was performed on ctDNA and germline DNA to..

View full abstract

University of Melbourne Researchers

Arun Azad Author

Related Projects (2)

VCA CLINICAL RESEARCH FELLOWSHIP

PROFILING CIRCULATING DNA AND RNA TO IDENTIFY MECHANISMS OF THERAPEUTIC RESISTENCE AND RESPONSE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Enzalutamide is a powerful hormone treatment that improves survival for men with advanced prostate cancer. Unfortunately, all prostate cance..

Grants

Awarded by National Institutes of Health

Funding Acknowledgements

This study was supported by: NHMRC Postgraduate Scholarship (to EdmondMKwan); Movember/Prostate Cancer Foundation of Australia Clinical Scientist Fellow (CSA 0515; to Kate Mahon); the Astellas Investigator-Initiated Grant, Cancer Institute NSW Translational Program Grant (2018/TPG001; to Lisa G Horvath); the NHMRC Project Grant, Victorian Cancer Agency Clinical Research Fellowship-CRF14009, Astellas Investigator-Initiated Grant, NHMRC Project Grant - GNT1098647 (to Arun A Azad); and the National Institute of Health-RO1-CA212097 (to Manish Kohli).